194 related articles for article (PubMed ID: 17875803)
21. CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma.
Li Y
N Engl J Med; 2019 Jan; 380(5):497. PubMed ID: 30702241
[No Abstract] [Full Text] [Related]
22. CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma.
Advani R; Volkmer JP; Chao MP
N Engl J Med; 2019 Jan; 380(5):497-498. PubMed ID: 30699313
[No Abstract] [Full Text] [Related]
23. Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.
Delaloye AB; Antonescu C; Louton T; Kuhlmann J; Hagenbeek A
J Nucl Med; 2009 Nov; 50(11):1837-43. PubMed ID: 19837764
[TBL] [Abstract][Full Text] [Related]
24. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group.
Cairo M; Auperin A; Perkins SL; Pinkerton R; Harrison L; Goldman S; Patte C
Br J Haematol; 2018 Sep; 182(6):859-869. PubMed ID: 29984828
[TBL] [Abstract][Full Text] [Related]
25. Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future.
Sorge CE; McDaniel JK; Xavier AC
Pharmaceuticals (Basel); 2016 May; 9(2):. PubMed ID: 27213405
[TBL] [Abstract][Full Text] [Related]
26. Antibody therapies for lymphoma in children.
de Zwart V; Gouw SC; Meyer-Wentrup FA
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011181. PubMed ID: 26784573
[TBL] [Abstract][Full Text] [Related]
27. Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.
Huang MA; Krishnadas DK; Lucas KG
J Immunol Res; 2015; 2015():675269. PubMed ID: 26587548
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy in pediatric malignancies: current status and future perspectives.
Capitini CM; Otto M; DeSantes KB; Sondel PM
Future Oncol; 2014; 10(9):1659-78. PubMed ID: 25145434
[TBL] [Abstract][Full Text] [Related]
29. Antibody therapy of pediatric B-cell lymphoma.
Meyer-Wentrup F; de Zwart V; Bierings M
Front Oncol; 2013; 3():68. PubMed ID: 23565504
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy of childhood cancer: from biologic understanding to clinical application.
Wayne AS; Capitini CM; Mackall CL
Curr Opin Pediatr; 2010 Feb; 22(1):2-11. PubMed ID: 19952749
[TBL] [Abstract][Full Text] [Related]
31. Immune-based therapeutics for pediatric cancer.
Capitini CM; Mackall CL; Wayne AS
Expert Opin Biol Ther; 2010 Feb; 10(2):163-78. PubMed ID: 19947897
[TBL] [Abstract][Full Text] [Related]
32. Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.
Macy ME; Sawczyn KK; Garrington TP; Graham DK; Gore L
Curr Oncol Rep; 2008 Nov; 10(6):477-90. PubMed ID: 18928662
[TBL] [Abstract][Full Text] [Related]
33. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ
Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
[TBL] [Abstract][Full Text] [Related]
34. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Wiseman GA; White CA; Sparks RB; Erwin WD; Podoloff DA; Lamonica D; Bartlett NL; Parker JA; Dunn WL; Spies SM; Belanger R; Witzig TE; Leigh BR
Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315
[TBL] [Abstract][Full Text] [Related]
35. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.
Witzig TE
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S91-5. PubMed ID: 11587375
[TBL] [Abstract][Full Text] [Related]
36. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
Alcindor T; Witzig TE
Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764
[TBL] [Abstract][Full Text] [Related]
37. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
[TBL] [Abstract][Full Text] [Related]
38. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
